UK markets closed
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • FTSE 250

    18,636.98
    -29.80 (-0.16%)
     
  • AIM

    875.21
    -1.01 (-0.12%)
     
  • GBP/EUR

    1.1593
    -0.0018 (-0.16%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.59%)
     
  • BTC-GBP

    15,890.18
    -44.14 (-0.28%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • DOW

    31,097.26
    +321.83 (+1.05%)
     
  • CRUDE OIL

    108.46
    +2.70 (+2.55%)
     
  • GOLD FUTURES

    1,812.90
    +5.60 (+0.31%)
     
  • NIKKEI 225

    25,935.62
    -457.42 (-1.73%)
     
  • HANG SENG

    21,859.79
    -137.10 (-0.62%)
     
  • DAX

    12,813.03
    +29.26 (+0.23%)
     
  • CAC 40

    5,931.06
    +8.20 (+0.14%)
     

How has the Dechra Pharmaceuticals share price performed over the past year?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

With areas of the economy continuing to come under pressure, stock market investors have been laser-focused on the share prices of some of the UK’s biggest companies - including Dechra Pharmaceuticals (LON:DPH).

Dechra Pharmaceuticals is one of just 200 UK-quoted stocks with a market capitalisation of more than £1 billion. In fact, the stock is currently valued at £3,809m. These top tier shares include some of the world’s best known companies. They have a huge presence in the investment funds and pension portfolios of millions of savers. They are also some of the biggest dividend payers.

So how have shares in Dechra Pharmaceuticals performed? Well, over the past 12 months, the stock has seen an absolute return of -15.4%.

Given that economic uncertainty has rocked some industry sectors very badly, it’s also worth looking at how the shares have performed in relation to the overall market.

On a relative basis, shares in Dechra Pharmaceuticals have moved by -18.6% over the past year and by -30.8% over the past six months.

But what now?

GET MORE DATA-DRIVEN INSIGHTS INTO LON:DPH »

Do analysts rate it as a buy, sell or hold?

Regardless of recent performance, the main concern for investors is what the future holds. In uncertain economic conditions, it's often difficult to get an accurate view. The good news when it comes to the market's biggest stocks is that analysts know these businesses better than most, so they are best-placed to make accurate predictions. That shows up in their Buy, Hold and Sell recommendations.

Among the analysts covering Dechra Pharmaceuticals, there are currently:

  • 2 Buy recommendations

  • 5 Hold recommendations

  • 0 Sell recommendations

With this kind of information, it's possible to start forming a view about the outlook for any share. A combination of recent price performance and analyst recommendations gives you a flavour of whether the market is expecting a bright future - or whether there are causes for concern.

What does this mean for potential investors?

Dechra Pharmaceuticals is one of the most closely watched shares in the market. But while price trends and broker recommendations can give you an idea about the sentiment around a stock, they can't tell you everything.

To get a better understanding of the overall investment case, it's worth doing some investigation yourself. Indeed, we've identified some areas of concern with Dechra Pharmaceuticals that you can find out about here.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting